X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs NOVARTIS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA NOVARTIS TORRENT PHARMA/
NOVARTIS
 
P/E (TTM) x 36.7 295.9 12.4% View Chart
P/BV x 5.7 25.2 22.7% View Chart
Dividend Yield % 1.0 1.4 65.9%  

Financials

 TORRENT PHARMA   NOVARTIS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
NOVARTIS
Mar-17
TORRENT PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,768855 206.8%   
Low Rs1,186666 178.1%   
Sales per share (Unadj.) Rs346.1219.0 158.0%  
Earnings per share (Unadj.) Rs55.219.1 288.9%  
Cash flow per share (Unadj.) Rs73.320.3 361.2%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %0.91.3 72.1%  
Book value per share (Unadj.) Rs257.1307.0 83.7%  
Shares outstanding (eoy) m169.2229.96 564.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.33.5 122.9%   
Avg P/E ratio x26.839.8 67.2%  
P/CF ratio (eoy) x20.137.5 53.8%  
Price / Book Value ratio x5.72.5 231.9%  
Dividend payout %25.452.4 48.5%   
Avg Mkt Cap Rs m249,88722,779 1,097.0%   
No. of employees `00011.80.7 1,747.9%   
Total wages/salary Rs m9,9341,393 713.1%   
Avg. sales/employee Rs Th4,971.59,736.2 51.1%   
Avg. wages/employee Rs Th843.22,066.8 40.8%   
Avg. net profit/employee Rs Th792.4849.0 93.3%   
INCOME DATA
Net Sales Rs m58,5696,562 892.5%  
Other income Rs m2,233702 318.3%   
Total revenues Rs m60,8027,264 837.1%   
Gross profit Rs m13,773259 5,319.7%  
Depreciation Rs m3,06936 8,549.3%   
Interest Rs m2,0567 28,550.0%   
Profit before tax Rs m10,881917 1,186.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545345 447.7%   
Profit after tax Rs m9,336572 1,631.6%  
Gross profit margin %23.53.9 596.0%  
Effective tax rate %14.237.6 37.7%   
Net profit margin %15.98.7 182.8%  
BALANCE SHEET DATA
Current assets Rs m53,8419,731 553.3%   
Current liabilities Rs m31,6121,830 1,727.0%   
Net working cap to sales %38.0120.4 31.5%  
Current ratio x1.75.3 32.0%  
Inventory Days Days9749 199.6%  
Debtors Days Days8425 333.0%  
Net fixed assets Rs m42,07957 73,565.2%   
Share capital Rs m846141 601.4%   
"Free" reserves Rs m42,6559,056 471.0%   
Net worth Rs m43,5019,196 473.0%   
Long term debt Rs m22,4080-   
Total assets Rs m101,25011,499 880.5%  
Interest coverage x6.3128.4 4.9%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.6 101.4%   
Return on assets %11.35.0 223.3%  
Return on equity %21.56.2 344.9%  
Return on capital %19.610.1 195.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,066129 15,567.4%   
Fx outflow Rs m5,3041,734 305.9%   
Net fx Rs m14,762-1,605 -919.8%   
CASH FLOW
From Operations Rs m10,127-380 -2,668.5%  
From Investments Rs m-7,8694,208 -187.0%  
From Financial Activity Rs m-1,918-3,318 57.8%  
Net Cashflow Rs m212510 41.5%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 2.0 351.0%  
FIIs % 12.6 1.6 787.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 21.5 40.9%  
Shareholders   26,511 41,647 63.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  CIPLA  NATCO PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - DR. REDDYS LAB COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS